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INTRODUCTION
The estimated worldwide prevalence of RA is 1 – 2%
that increases with age, approaching 5%  in women over
age 55.1 In a study done on adults from northern
Pakistan, a high overall burden of rheumatic diseases
has been shown, and the prevalence of RA was
calculated to be 5.5 per 1000.2 A recent report from a
rheumatology clinic in Karachi showed 12.9% of adult
patients to be suffering from RA and of these 3.5%
had extra-articular complications.3 A survey of joint
symptoms among 4232 adults, evenly distributed
between poor and affluent areas of Karachi, Pakistan
reported the prevalence of RA as 0.9 and 1.98 per
thousand in the two areas, respectively.4
The focus of recent research was on the development
of markers for early diagnosis of RA to prevent absolute
crippling deformity of joints and extra articular
complications involving lungs, pericardium and the
sclera.5 Since the discovery of RF by Waaler in 1940, its
role in the pathogenesis of RA and its diagnostic utility
has been widely investigated. Changes in serum RF
levels are used as indicators of disease activity, and in
monitoring responses to therapy, especially to biological
disease modifiers.6-10 However, the RF test is not always
discriminative. High serum levels of RF have also been
reported in chronic viral infections such as infection from
hepatitis C virus and bacterial endocarditis.11,12
Antibodies to cyclin citrullinated antigen (anti-CCP) bind
to antigenic determinants that contain the amino acid
citrulline, a reaction catalyzed by the enzyme peptidyl
arginine deiminase that involves post-transcriptional
modification of arginine residues. These antibodies have
been shown to be the same as antikeratin and anti-
filaggrin which have been described to play a significant
role in the pathogenesis of RA.14
This study was conducted to compare the utility of
anti-CCP and RF in the diagnosis of RA in patients
presenting with pain to medical clinics at the Aga Khan
University Hospital (AKUH), Karachi.
METHODOLOGY
This cross-sectional analytical study was undertaken at
the Section of Chemical Pathology, Department of
Pathology and Microbiology and the Bone and
Rheumatology Clinic, Department of Medicine at the
AKUH, Karachi. A review of medical records of patients
presenting to the clinics of medicine, metabolic bone
diseases and rheumatology AKUH with complaints of
muscular or joint pains and who were tested for their
serum anti-CCP levels from 1st January 2010 to 31st May
2010 at the Clinical Laboratory of AKUH was performed.
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A preformed questionnaire comprising of demographic
and clinical details about symptoms and signs of the
patients were recorded along with the duration of the
symptoms, values of erythrocyte sedimentation rate
(ESR) and the serum levels of C-reactive protein (CRP),
RF and anti-CCP. The study was approved by ethical
review committee of AKUH for publication.
Scoring for RA was performed using the 2010
Rheumatoid Arthritis Classification Criteria by American
College of Rheumatology (ACR) for each patient.13 The
criterion was applied only to eligible patients, in whom
the presence of obvious clinical synovitis in at least 1
joint was present and there was an absence of
alternative diagnosis. Patients with mere arthralgia were
excluded. Criteria had four categories which were
included in the proforma as joint involvement, serology,
acute phase reactants and duration of symptoms.
To classify a patient as having or not having definite
RA, a history of symptom duration, a thorough joint
evaluation, and at least one serologic test (RF or anti-
CCP) and one acute-phase response measure (ESR or
CRP) were evaluated.
Levels of anti-CCP < 17 U/ml were considered normal,
17-51 U/ml as low-level positive and values > 51 U/ml as
high-level positive. The levels of RF < 14 U/ml were
considered normal, 14 – 42 U/ml as low-level positive
and values > 42 U/ml as high-level positive.
As per ACR criteria, an individual patient may meet the
definition of RA without the need of all tests. However,
for the purposes of research, documentation of each
domain was done. A cut-off of ≥ 6 was used to classify
the patients as RA.
Serum anti-CCP was assayed (using a second
generation anti-CCP assay kit) by electrochemilu-mine-
scence on automated analyzer, Cobas 601 (Roche
Diagnostics, USA). Quality controls provided by the
manufacturer (Elecsys Preci Control anti-CCP 1 and 2)
were run with every batch analyzed. The within-run CVs
were 3.1% and 2.5% at concentrations of 16.9 U/ml and
356 U/ml. The measuring range of the assay was
7 – 500 U/ml. Samples with anti-CCP concentrations
above the measuring range were diluted 1:2 to 1:5
manually.
Serum RF was analyzed by photometry on Hitachi
(Roche Diagnostics, USA). The system was closely
monitored by routine practice of running both high and
low controls with every batch analyzed. The within-run
CV was 1.48% at concentration 18.1 IU/ml and 0.46 at
55.2 IU/ml. The day-to-day precision was 4.66% and
2.48% at concentrations 17.5 IU/ml and 57.7 IU/ml
respectively.
Erythrocyte sedimentation rate was measured using the
Westergren method. The system for ESR was monitored
by two point calibration. The laboratory also successfully
participated biannually in external quality control system
by College of American Pathologists (CAP) for ESR.
Values of ESR greater than 20 and 15 mm/hour were
considered abnormal for females and males respec-
tively.
Serum CRP was analyzed on Synchron CX 9 (Beckman,
USA). Low, normal and high controls were run with each
batch. The within-run and total CVs were 5% and 7%
respectively. It was also closely monitored by biannual
participation in external proficiency program of CAP.
Values of CRP greater than 1 mg/dl were considered
abnormal.
Statistical Package for Social Sciences (SPSS) version
19 was used for statistical analysis of the data. A p-value
< 0.05 was considered significant throughout. Median
and interquartile range (IQR) for quantitative variables
was computed. Receiver operator curves (ROC) were
generated and areas under the curves (AUC) were
calculated. The AUC was used as an index in evaluating
the inherent capacity of the two antibodies to
discriminate between “positive” and “negative” RA
cases. The sensitivity, specificity, positive predictive and
negative predictive values were calculated for both RF
and anti-CCP. An association between the scores and
anti-CCP levels was analyzed using Spearman's
correlation. Kolmogorov test was applied for checking
the normality of data distribution (p value < 0.05). Mann
Whitney U-test was applied to compare anti-CCP levels
between RA positive and negative groups.
RESULTS
During the study period, 98 patients presented with
symptoms of muscular and joint pains in ambulatory
care and investigated for anti-CCP at Clinical Laboratory
of AKUH. The mean age of the patients was 46.5 ± 15
years. It consisted of 81 females (82.7%) and 17 males
(17.3%). Out of the total, 53 patients were classified as
RA (ACR score ≥ 6) and 45 as RA negative (ACR score
< 6) based on ACR criteria. A summary of the patients'
clinical symptomatology that was collected from the
questionnaire is presented in Table I. Joint pain, swelling
and stiffness were the predominant symptoms. The
disease chiefly affected the small joints of the hands,
though almost all the joints in the body were affected to
some extent. Number of joint involvement is reflected in
higher ACR scores.
The median anti-CCP levels in 98 cases was 3.5 IU/ml
(IQR = 3.5 – 500).  Out of the total, 31 patients had anti-
CCP levels > 17 IU/ml (median 374 U/ml, IQR =
19.3 – 500 IU/ml), 21 of these individuals had RA on
the basis of ACR score. Levels of anti-CCP were within
normal reference range in 67 patients (median 3.5 U/ml
IQR = 3.5 – 12.7 IU/ml). The ROC analysis revealed
AUC of 0.76 for anti-CCP as depicted in Figure 1
(p < 0.01).
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Median anti-CCP levels showed a rising trend with
increasing ACR scores. The levels of anti-CCP were
positively correlated with their ACR scores using the
Spearman's correlation whereby ‘r’ was calculated as
0.58 (p < 0.01). Mann Whitney U-test showed that
patients with RA (ACR score ≥ 6) had significantly
higher anti-CCP levels as compared to those without RA
(ACR score < 6) (p < 0.001).
Fifty eight individuals out of the 98 were tested for both
auto-antibodies, anti-CCP and RF as a diagnostic
workup. Out of them, 48 were females (82.8%) and 10
were males (17.3%). Their mean age was 46 ± 15 years.
There were 32 patients who had a score ≥ 6 (RA
positive). Amongst them 87.5% were females. Their anti-
CCP and RF titers have been recorded in Table II.
Comparison of the diagnostic utility of anti-CCP and RF
is shown in Table III. While, RF was more sensitive as
compared to anti-CCP, anti-CCP was more specific with
a higher positive and negative predictive values. The
ROC analysis revealed AUC of 0.74 for RF (p < 0.01).
Positivity of either auto-antibody (either RF or anti-CCP)
did not increase the sensitivity or specificity for detecting
RA.
DISCUSSION
The importance of anti-CCP as a diagnostic and
prognostic marker for RA has been elucidated widely in
the developed world.  Majority of the studies published
have assessed the diagnostic properties of anti-CCP in
concerned patients with confirmed RA according to the
ACR 1987 revised criteria.14 The 1987 ACR classifi-
cation criteria for RA have been criticized for their lack of
sensitivity in early disease. For the first time in this study,
the diagnostic performance of anti-CCP was assessed
against the new 2010 ACR classification criteria for RA.
This classification system re-defines RA by focusing on
features at earlier stages of disease that are associated
with persistent and/or erosive disease, rather than
defining the disease by its late-stage features.
High anti-CCP titers in the patient population in this
study were able to differentiate musculoskeletal pain
that originated as a result of RA from other medical
conditions that resulted in the same symptomatology.
The greater specificity of anti-CCP than RF has been
indicated in many studies in the world but none so far
Role of anti-CCP in rheumatoid arthritis
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Figure 1: Receiver-operating characteristic curve of anti-CCP levels.
Table I: Symptomatology of patients presenting with pain to medical
clinics of the Aga Khan University Hospital, Karachi, Pakistan (n = 98).
Clinical symptoms Results n (%)
Joint pain 93.9 (92)
Joint swelling 52.04 (51)
Joint stiffness 63.27 (62)
Fever 16.3 (16)
Unilateral shoulder joint involvement 09.1 (9)
Bilateral shoulder joint involvement 31.6 (31)
Unilateral elbow involvement 08.2 (8)
Bilateral elbow involvement 06.1 (6)
Hip joint involvement 16.3 (16)
Unilateral knee involvement 03.06 (3)
Bilateral knee involvement 41.8 (41)
Ankle involvement 20.4 (20)
Small joints involvement 46.9 (46)
Table II: Comparison of variables of ACR classification among RA positive
versus RA negative patients (n = 58).
Variable in ACR classification RA positive RA negative
ACR Score ≥ 6* ACR Score < 6*
n = 32 n = 26
RF  IU/ml  (IQR) 21.2 (3.5-329.4) 7.8 (3.5-23.5)
Anti-CCP IU/ml (IQR) 43.1 (3.5-500) 3.5 (3.5-500)
Haemoglobin in gm/dl (IQR) 11.5 (7.2-14.4) 12.8  (8.6-15.3)
Joint pain in %  (n) 100 (30) 89.28  (25)
Joint swelling in % (n) 77.8  (20) 29.6 (8)
Joint stiffness in % (n) 48.4  (14) 22.2  (6)
Patients having a joint involvement 
score > 2 in %  (n) 64.5 (20) 44.4  (12)
Patients with raised acute phase  
reactants in % (n) 63.3 (18) 48.1  (13)
*2010 Rheumatoid Arthritis Classification Criteria by American College of Rheumatology [28].
ACR = American College of Rheumatology;    RA = rheumatoid arthritis;    anti-CCP = antibodies
to cyclin citrullinated antigen.
Table III: Diagnostic utility of anti-CCP (n = 98) and RF (n = 58) with ACR scores ≥ 6 (RA positive) and ACR score < 6 (RA negative).
Auto Antibodies (n) Cutoffs (IU/ml) RA positive RA negative Sensitivity Specificity Positive predictive Negative predictive Area under
ACR score ≥ 6* ACR score < 6* % % value % value % the curve
anti-CCP (98) ≥ 17 29 02
< 17 24 43 54.7 95.5 93.5 64.1 0.75
RF (58) ≥ 14 19 03
< 14 13 23 59.3 88.4 86.3 63.8 0.74
* 2010 Rheumatoid Arthritis Classification Criteria by American College of Rheumatology (ACR) [28].   anti-CCP = antibodies to cyclin citrullinated antigen;    RF = rheumatoid factor;       
ACR = American College of Rheumatology;     RA = rheumatoid arthritis;     anti-CCP = antibodies to cyclin citrullinated antigen.
from Pakistan.15,16 In this study of patients who were
diagnosed with RA, the greater specificity of anti-CCP
over RF was further validated. Specificity of anti-CCP in
diagnosing RA is comparable to previously published
studies and meta-analysis.17-20 A wide range of anti-CCP
sensitivities have been reported by these authors
ranging from 41 to 87.6%. In a systemic analysis, on the
use of anti-CCP in RA patients, Avouac et al. reported a
diagnostic sensitivity of 39 – 94%.18 This wide variability
in sensitivity is attributed to varying anti-CCP cutoff value
in defining a positive test, differing patient populations,
and the use of assays with varying principle by different
manufacturers. This was also observed by Garcia-
Berrocal who revealed differences between three anti-
CCP second-generation enzyme linked immunosorbent
assay (ELISA).19
High titers of anti-CCP also corresponded with the
severity of symptoms as indicated by higher serum
values in patients with more severe disease as judged
by the symptoms score in ACR scoring system. In an
earlier study, the anti-CCP levels correlated with disease
activity parameters in 379 early RA patients where it was
assessed at baseline and then radiological joint damage
and progression were assessed after 2 years of follow-
up. The univariate predictor analysis showed that anti-
CCP had the highest significant odds ratio for radio-
logical joint damage.20 In another study, anti-CCP testing
was done on 242 RA patients who were followed for 3
years. Anti-CCP antibodies were positively correlated
with higher acute phase reactants, swollen joint count,
and worse physician global assessment ratings.21
Multiple studies have shown that anti-CCP positive early
RA patients develop a more erosive disease than those
without anti-CCP and it has been validated as a marker
of erosive disease in RA.22-24 In the present study, anti-
CCP showed a higher specificity, a greater positive and
negative predictive values but lower sensitivity
compared to RF. All diagnostic parameters were highly
significant statistically.
The common medical regimen that is prescribed to
combat RA includes non-steroidal anti-inflammatory
agents, methotrexate, steroids, sulfonamides and
disease modifying anti-rheumatic agents, all of which
have serious adverse effects. RF has been shown to
be a non-specific marker repeatedly; its use as a
confirmatory test for RA should be avoided. RF factor
positivity can be confusing in areas like ours where
prevalence of hepatitis is high especially when the
patients present with arthralgia. This can be avoided by
the judicious use of anti-CCP.
CONCLUSION
The specificity is the most valuable aspect of anti-CCP
for diagnosing RA in a population where there is a high
disease burden of chronic hepatitis. Its low sensitivity
does not allow its use as a screening test but can be
used in conjunction with RF.  Its induction in the normal
protocol in diagnosing RA is necessary. It is, therefore,
desirable to popularize its use amongst rheumatologists
throughout Pakistan.
REFERENCES
1. Myasoedova E, Crowson CS, Kremers HM, Therneau TM,
Gabriel SE. Is the incidence of rheumatoid arthritis rising?:
results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum
2010; 62:1576-82.
2. Farooqi A, Gibson T. Prevalence of the major rheumatic
disorders in the adult population of north Pakistan. Br J Rheumatol
1998; 37:491-5.
3. Alam SM, Kidwai AA, Jafri SR, Qureshi BM, Sami A, Qureshi
HH, et al. Epidemiology of rheumatoid arthritis in a tertiary care
unit, Karachi, Pakistan. J Pak Med Assoc 2011; 61:123-6.
4. Hameed K, Gibson T, Kadir M, Sultana S, Fatima Z, Syed A. The
prevalence of rheumatoid arthritis in affluent and poor urban
communities of Pakistan. Br J Rheumatol 1995; 34:252-6.
5. Smolen JS, Tohidast-Akrad M, Gal A, Kunaver M, Eberl G, Zenz
P, et al. The role of T-lymphocytes and cytokines in rheumatoid
arthritis. Scand J Rheumatol 1996; 25:1-4.
6. Ilowite NT, O'Reilly ME, Hatam L, Wedgwood JF, Bonagura VR.
Expression of the rheumatoid factor cross-reactive idiotype in
JRA: association with disease onset subtype, disease activity
and disease severity. Scand J Rheumatol 1992; 21:51-4.
7. Dabadghao S, Misra R, Naveed M, Aggarwal A. IgM rheumatoid
factor estimation by ELISA in seronegative rheumatoid arthritis
before and after IgM fractionation: does seronegative RA exist?
Rheumatol Int 1996; 15:189-93.
8. van Laar JM. Do high levels of IgA rheumatoid factor indicate a
poor response to treatment with TNF inhibitors in patients with
RA? Nat Clin Pract Rheumatol 2007; 3:544-5. Epub 2007
Aug 28.
9. Mikuls TR, O'Dell JR, Stoner JA, Parrish LA, Arend WP, Norris
JM, et al. Association of rheumatoid arthritis treatment response
and disease duration with declines in serum levels of IgM
rheumatoid factor and anti-cyclic citrullinated peptide antibody.
Arthritis Rheum 2004; 50:3776-82.
10. Mottonen T, Paimela L, Leirisalo-Repo M, Kautiainen H, Ilonen J,
Hannonen P. Only high disease activity and positive rheumatoid
factor indicate poor prognosis in patients with early rheumatoid
arthritis treated with "sawtooth" strategy. Ann Rheum Dis 1998;
57:533-9.
11. Riccio A, Conca P, Marzocchella C, Tarantino G. Rheumatoid
factor after anti-viral therapy in patients with HCV chronic hepatitis.
Clin Exp Rheumatol 2008; 26:926-8.
12. Gouriet F, Bothelo-Nevers E, Coulibaly B, Raoult D, Casalta JP.
Evaluation of sedimentation rate, rheumatoid factor, C-reactive
protein, and tumour necrosis factor for the diagnosis of infective
endocarditis. Clin Vaccine Immunol 2006; 13:301.
13. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham
CO, 3rd, et al. 2010 Rheumatoid arthritis classification criteria:
an American College of Rheumatology/European League
against rheumatism collaborative initiative. Arthritis Rheum
2010; 62:2569-81.
Aysha Habib Khan, Lena Jafri, M. Ahraz Hussain and Saliha Ishaq
714 Journal of the College of Physicians and Surgeons Pakistan 2012, Vol. 22 (11): 711-715
 
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS, et al. The American Rheumatism Association 1987
revised criteria for the classification of rheumatoid arthritis.
Arthritis Rheum 1988; 31:315-24.
15. Erre GL, Tocco A, Faedda R, Cossu A, Carcassi A. [Diagnostic
and prognostic value of antibodies to cyclic citrullinated peptide
(anti-CCP) in rheumatoid arthritis]. Reumatismo 2004; 56:
118-23.
16. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt
RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific
autoantibodies precede the symptoms of rheumatoid arthritis: a
study of serial measurements in blood donors. Arthritis Rheum
2004; 50:380-6.
17. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T,
Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-
cyclic citrullinated peptide antibody and rheumatoid factor for
rheumatoid arthritis. Ann Intern Med 2007; 146:797-808.
18. Avouac J, Gossec L, Dougados M. Diagnostic and predictive
value of anti-cyclic citrullinated protein antibodies in rheumatoid
arthritis: a systematic literature review. Ann Rheum Dis 2006;
65:845-51. Epub 2006 Apr 10.
19. Greiner A, Plischke H, Kellner H, Gruber R. Association of anti-
cyclic citrullinated peptide antibodies, anti-citrullin antibodies,
and IgM and IgA rheumatoid factors with serological parameters
of disease activity in rheumatoid arthritis. Ann NY Acad Sci 2005;
1050:295-303.
20. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B.
Prediction of radiological outcome in early rheumatoid arthritis in
clinical practice: role of antibodies to citrullinated peptides (anti-
CCP). Ann Rheum Dis 2004; 63:1090-5.
21. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP anti-
body test predicts the disease course during 3 years in early
rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis
2004; 63:1085-9.
22. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den
Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic
citrullinated peptide antibody in patients with recent-onset of
rheumatoid arthritis. Arthritis Rheum 2000; 43:1831-5.
23. Kaltenhauser S, Pierer M, Arnold S, Kamprad M, Baerwald C,
Hantzschel H, et al. Antibodies against cyclic citrullinated
peptide are associated with the DRB1 shared epitope and
predict joint erosion in rheumatoid arthritis. Rheumatology
(Oxford) 2007; 46:100-4. Epub 2006 May 25.
24. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibody, a
marker for the early detection of rheumatoid arthritis. Ann NY
Acad Sci 2008; 1143:268-85.
Role of anti-CCP in rheumatoid arthritis
Journal of the College of Physicians and Surgeons Pakistan 2012, Vol. 22 (11): 711-715 715
